Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study

BACKGROUND: Dapagliflozin is one of the novel glucose-lowering agents, which has recently been reported to reduce the risk of hospitalization for heart failure (hHF). The present study aimed to compare the differences between the risk of hHF after using dapagliflozin and dipeptidyl peptidase-4 inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Seong, Jong-Mi, Kim, Jong Joo, Kim, Hae Jin, Sohn, Hyun Soon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310428/
https://www.ncbi.nlm.nih.gov/pubmed/32571319
http://dx.doi.org/10.1186/s12933-020-01060-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310428/
https://www.ncbi.nlm.nih.gov/pubmed/32571319
http://dx.doi.org/10.1186/s12933-020-01060-1

Ejemplares similares